Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced promising results from its Phase 2 trial of NBI-1117568, a first-in ...

WALTHAM, Mass. and BOULDER, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology ...

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

Krystal Biotech's KRYS short percent of float has risen 9.9% since its last report. The company recently reported that it has ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive ...

WASHINGTON: United States President Donald Trump's administration on Wednesday (May 29) canceled a US$590 million contract ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 2025 ...

Alamar Biosciences enters strategic collaboration with SciLifeLab to advance translational proteomics and accelerate biomarker discovery: Fremont, California Thursday, May 29, 202 ...

But on Wednesday, May 28 Moderna revealed the HHS has terminated the award for late-stage development and right to purchase ...

Checkpoint Therapeutics Inc.'s planned $355 million sale to Sun Pharmaceuticals Inc. will likely siphon value from public ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

PepGen Inc. (NASDAQ:PEPG) expects data from its Phase 1 FREEDOM-DM1 trial’s 15 mg/kg cohort in the second half of 2025, and ...